Bitte aktivieren Sie Javascript um alle Funktionen nutzen zu können und ihre Nutzererfahrung zu verbessern.
EHC 2024
Programm
Poster
Suche
DE
Poster zum Thema "CGRP (receptor) inhibitors in the clinic"
Zurück
P001
ePoster
Constipation as an adverse effect of all the subcutaneous anti CGRP monoclonal antibodies: relation to pre-existing constipation and impact on migraine treatment
Teresa Ascensão Pinheiro (Amadora, PT)
P002
ePoster
Calcitonin gene-related peptide monoclonal antibodies and concomitant autoimmune related disorders
Bruno Carvalho (Porto, PT)
P003
ePoster
Blood pressure in migraine patients undergoing treatment with CGRP monoclonal antibodies in patients with migraine – a systematic review and potential implications for clinical practice
Britt W.H. van der Arend (Leiden, NL; Rotterdam, NL)
P004
ePoster
Anti-CGRP monoclonal antibodies treatment discontinuation in migraine: when and why
Teresa Mateu (Barcelona, ES; Mollet del Vallès, ES)
P005
ePoster
Efficacy and safety of rimegepant for the preventive treatment of fasting-related headache during Ramadan in the UAE
Taoufik Alsaadi (Abu Dhabi, AE)
P006
ePoster
Efficacy and safety of rimegepant for the acute treatment of migraine in Japan
Terence Fullerton (Groton, CT, US)
P007
ePoster
Efficacy and safety of rimegepant for the prevention of migraine in Japan
Terence Fullerton (Groton, CT, US)
P008
ePoster
Consistency of effect of rimegepant as an acute treatment for migraine attacks: Data from a real-world survey
Lucy Abraham (Tadworth, GB)
P009
ePoster
Cognitive improvement in a patient undergoing Eptinezumab for the treatment of chronic migraine – a case report
Mona Hirt (Zürich, CH)
P010
ePoster
Real-world effectivenes and tolerability of switching between CGRP pathway tageting antibodies: Czech Migraine Registry (ReMig)
Tomáš Nežádal (Prague, CZ)
P011
ePoster
Fremanezumab for the treatment of migraine and medication overuse headache – a systematic review and meta-analysis
Lanfranco Pellesi (Odense, DK)
P012
ePoster
Effectiveness and safety of anti-CGRP treatment in migraine patients with autoimmune diseases: multicenter "ImmunoCGRP" case-control study
Alicia González Martínez (Madrid, ES)
P092
ePoster
Eptinezumab treatment in patients with previous anti-CGRP(R) monoclonal antibodies therapy (mAbs) – a retrospective study of real-world clinical evidence of efficacy
Alessia Bellotti (Perugia, IT; Lugano, CH)
P093
ePoster
Effectiveness and tolerability of lasmiditan in the acute migraine treatment (DART) – a real-world multicentric study
Gloria Vaghi (Pavia, IT)
P094
ePoster
Evaluating safety, effectiveness, and impact on multiple sclerosis disease course of Anti-CGRP monoclonal antibodies combined with disease-modifying treatments – a multicentric study
Marina Romozzi (Rome, IT)
P095
ePoster
A multidisciplinary multicentric approach to the identification of BIOmarkers of MIGraine (BIOMIGA project): an open-label, prospective biochemical study based on the stratification of responders to Erenumab
Maria Magdalena Pocora (Pavia, IT)
P096
ePoster
Effectiveness and tolerability of fremanezumab in real-world clinical practice:Results of the 24-month prospective observational study FINESSE
Andreas Straube (Munich, DE)
P097
ePoster
Real-world long-term effectiveness of fremanezumab in patients with migraine who switched from another mAb targeting the CGRP pathway – subgroup analysis of the FINESSE full analysis
Andreas Straube (Munich, DE)
P098
ePoster
Lessons with fremanezumab as the third CGRP antibody in our hospital: focus on factors predicting response
Marcos Polanco Fernández (Santander, ES)
P099
ePoster
Restarting migraine preventive treatment with CGRP antibodies after drug holiday: Insights from Pavia real-world experience
Luca Costantino (Pavia, IT)
P100
ePoster
Clinical impact of Rimegepant in acute migraine management for triptan non-responders
Davide Mascarella (Bologna, IT)
P101
ePoster
Switching anti-CGRP monoclonal antibodies benefits 25% of non-responders – an observational study of 82 cases
Albert Muñoz-Vendrell (Barcelona, ES)
P102
ePoster
Evaluating the efficacy of monoclonal antibodies targeting CGRP in migraine treatment and the effect of combination therapy with Onabotulinum Toxin Type-A – a retrospective study
Andreia Costa (Porto, PT)
P103
ePoster
Characteristics of people with migraine using rimegepant in the Adelphi migraine Disease Specific Programme
TM
(DSP)
Lucy Abraham (Tadworth, GB)
P250
ePoster
Real-life experience of rimegepant in episodic migraine
Celia Santillana Avila (Armilla, ES)
P251
ePoster
Anti-CGRP antibodies in patients with migraine and autoimmune disease with concomitant immunosuppressants/immunomodulators treatment: interactions, safety and effectiveness
Noelia Guerrero Carmona (Sevilla, ES)
P252
ePoster
Response to eptinezumab in chronic cluster headache – a case report
Jorge Madera Fernandez (Santander, ES)
P253
ePoster
Characteristics of patients prescribed rimegepant vs. all patients seeking migraine care via telemedicine
Motomori Lewis (New York, NY, US)
Lucy Abraham (Tadworth, GB)
P254
ePoster
Is Erenumab effective and safe in long term migraine treatment? A three-years observational study
Elisa Maria Bruno (Bologna, IT)
P255
ePoster
A 3-year migraine management with anti-CGRP monoclonal antibodies: an intention-to-treat analysis of real-world evidence
Elena Mazzotta (Pavia, IT)
P256
ePoster
The effect of 9-months fremanezumab preventive treatment on the triptan response and on the incidence of triggers and prodromal symptoms in patients with HFEM
Emmanouil V. Dermitzakis (Thessaloniki, GR)
P257
ePoster
Multi-parametric efficacy assessment of Eptinezumab in patients with chronic migraine and medication overuse headache – early results from a third level headache center
Danilo Antonio Montisano (Milano, IT)
P258
ePoster
Quarterly fremanezumab: assessing migraine relief and patient satisfaction
Cristina Trevino-Peinado (Leganés, ES)
P259
ePoster
Refractory chronic migraine: no symptomatic relief after 20 preventive medications
Stefanie Moreira (Braga, PT)
v1.20.0
© Conventus Congressmanagement & Marketing GmbH
Impressum
Datenschutz